These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12493791)

  • 21. Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin.
    Growcott EJ; Coulthard A; Amison R; Hardaker EL; Saxena V; Malt L; Jones P; Grevot A; Poll C; Osborne C; Banner KH
    J Cyst Fibros; 2011 May; 10(3):166-74. PubMed ID: 21247812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
    Bédos JP; Azoulay-Dupuis E; Moine P; Muffat-Joly M; Veber B; Pocidalo JJ; Vallée E
    J Pharmacol Exp Ther; 1998 Jul; 286(1):29-35. PubMed ID: 9655838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic disposition of temafloxacin and ciprofloxacin in a murine model of pneumococcal pneumonia. Relevance for drug efficacy.
    Vallée E; Azoulay-Dupuis E; Bauchet J; Pocidalo JJ
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1203-8. PubMed ID: 1326627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: effects of lung inflammation and timing of treatment.
    Dallaire F; Ouellet N; Simard M; Bergeron Y; Bergeron MG
    J Infect Dis; 2001 Jan; 183(1):70-7. PubMed ID: 11087202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
    Azoulay-Dupuis E; Bedos JP; Vallée E; Hardy DJ; Swanson RN; Pocidalo JJ
    J Infect Dis; 1991 Feb; 163(2):319-24. PubMed ID: 1988515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethanol impairs neutrophil chemotaxis in vitro but not adherence or recruitment to lungs of rats with experimental pneumococcal pneumonia.
    Lister PD; Gentry MJ; Preheim LC
    J Infect Dis; 1993 May; 167(5):1131-7. PubMed ID: 8517883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Penetration of Ciprofloxacin and Amikacin into the Alveolar Epithelial Lining Fluid of Rats with Pulmonary Fibrosis.
    Ni W; Yang D; Mei H; Zhao J; Liang B; Bai N; Chai D; Cui J; Wang R; Liu Y
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia.
    van den Boogaard FE; Hofstra JJ; van 't Veer C; Levi MM; Roelofs JJ; van der Poll T; Schultz MJ
    PLoS One; 2015; 10(5):e0127261. PubMed ID: 25992779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model Calculations of Regional Deposition and Disposition for Single Doses of Inhaled Liposomal and Dry Powder Ciprofloxacin.
    Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):49-60. PubMed ID: 28708440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia.
    Knapp S; Hareng L; Rijneveld AW; Bresser P; van der Zee JS; Florquin S; Hartung T; van der Poll T
    J Infect Dis; 2004 Apr; 189(8):1506-15. PubMed ID: 15073689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex-based differences in susceptibility to respiratory and systemic pneumococcal disease in mice.
    Kadioglu A; Cuppone AM; Trappetti C; List T; Spreafico A; Pozzi G; Andrew PW; Oggioni MR
    J Infect Dis; 2011 Dec; 204(12):1971-9. PubMed ID: 22021621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.
    Rijneveld AW; Weijer S; Bresser P; Florquin S; Vlasuk GP; Rote WE; Spek CA; Reitsma PH; van der Zee JS; Levi M; van der Poll T
    Crit Care Med; 2006 Jun; 34(6):1725-30. PubMed ID: 16625114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
    Pallares R; Liñares J; Vadillo M; Cabellos C; Manresa F; Viladrich PF; Martin R; Gudiol F
    N Engl J Med; 1995 Aug; 333(8):474-80. PubMed ID: 7623879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental infection of rhesus macaques with Streptococcus pneumoniae: a possible model for vaccine assessment.
    Philipp MT; Purcell JE; Martin DS; Buck WR; Plauché GB; Ribka EP; DeNoel P; Hermand P; Leiva LE; Bagby GJ; Nelson S
    J Med Primatol; 2006 Jun; 35(3):113-22. PubMed ID: 16764668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin.
    Schiffelers RM; Storm G; ten Kate MT; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 2001 Feb; 45(2):464-70. PubMed ID: 11158742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
    J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia.
    Rijneveld AW; Florquin S; Hartung T; Speelman P; van der Poll T
    J Infect Dis; 2003 Jul; 188(2):282-5. PubMed ID: 12854084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo efficacy of KRP-109, a novel elastase inhibitor, in a murine model of severe pneumococcal pneumonia.
    Yamada K; Yanagihara K; Araki N; Harada Y; Morinaga Y; Izumikawa K; Kakeya H; Yamamoto Y; Hasegawa H; Kohno S; Kamihira S
    Pulm Pharmacol Ther; 2011 Dec; 24(6):660-5. PubMed ID: 21864700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily variations in ceftriaxone pharmacokinetics in rats.
    Rebuelto M; Ambros L; Rubio M
    Antimicrob Agents Chemother; 2003 Feb; 47(2):809-12. PubMed ID: 12543699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.